Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections.
Eur J Pharm Biopharm. 2017 Sep;118:62-67. doi: 10.1016/j.ejpb.2016.11.026. Epub 2016 Nov 22.
Castoldi A1, Herr C2, Niederstraßer J2, Labouta HI3, Melero A4, Gordon S1, Schneider-Daum N1, Bals R2, Lehr CM5.
The lungs can activate vitamin D locally – a Vitamin D inhaler may help lungs – Aug 2016 has the following
Getting Vitamin D into your body has the following chart
- Nanoemulsion Vitamin D may be a substantially better form
- Vitamin D Emulsions - nano 2X better than coarse – Dec 2017
- Inhaled vitamin D helped lungs of new-born (rats) – Dec 2016
- Vitamin D nanoemulsion etc. for fortification, pills, injections, topical and cancer – July 2019
- Nanoemulsion vitamin D is again found to be the best liquid form (for rats in this case) – June 2019
- Inhaling Vitamin D nanoemulsion through nose gets lots more to the brain (mice) – July 2020
- Inhaled nanoemulsion of Vitamin D killed lung bacteria – Sept 2017
- Vitamin D nanoemulsion, with comments on COVID-19 – June 2, 2020
- Bioavailability of nanoemulsion formulations of Vitamin D3 – Nov 2019
- Vitamin D is activated by the lungs as well as most human tissues - no liver or kidney required
Download the PDF from VitaminDWiki
The influence of vitamin D3 and its metabolites calcifediol (25(OH)D) and calcitriol on immune regulation and inflammation is well described, and raises the question of potential benefit against bacterial infections. In the current study, 25(OH)D was encapsulated in liposomes to enable aerosolisation, and tested for the ability to prevent pulmonary infection by Pseudomonas aeruginosa. Prepared 25(OH)D-loaded liposomes were nanosized and monodisperse, with a negative surface charge and a 25(OH)D entrapment efficiency of approximately 23%. Jet nebulisation of liposomes was seen to yield an aerosol suitable for tracheo-bronchial deposition. Interestingly, 25(OH)D in either liposomes or ethanolic solution had no effect on the release of the proinflammatory cytokine KC from Pseudomonas-infected murine epithelial cells (LA-4); treatment of infected, human bronchial 16-HBE cells with 25(OH)D liposomes however resulted in a significant reduction in bacterial survival. Together with the importance of selecting an application-appropriate in vitro model, the current study illustrates the feasibility and practicality of employing liposomes as a means to achieve 25(OH)D lung deposition. 25(OH)D-loaded liposomes further demonstrated promising effects regarding prevention of Pseudomonas infection in human bronchial epithelial cells.